Avid Bioservices Inc (CDMO)

[entdoc]

cloaked, I don't get it: You said, "If Bavituximab would not work (which is certainly still an option for those that do not understand it in depth as I do now), then there is no "stall in a well-financed stable..." as endoc worded it for bavituximab."
You must have meant, "If Bavi does not work for I-O?" And as for understanding it in depth as you do now, you say there is no place for Bavi for any application?
The logic of these posts is often very difficult for me to follow, but then they might be more understandable for those who understand Bavi in such depth as you do.
My point is, and always has been, that it is nonsense to expect Bavi to impact end-stage lung cancer. I haven't said that about cancers that are detected in, say, a sub-centimeter size. Antiphospolipid antibody inquiry seems sensible to me in many other applications than immune-oncology, and PPHM certainly has a lead in that sector. The rapid expansion of peer-reviewed articles in that space speaks volumes. Cheers!